Revised outcome of Board Meeting held on 25th August 2025. The earlier revised outcome uploaded has incorrect w.e.f date of appointment of statutory auditor. The correct w.e.f date is 25th August,2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma has issued a revised outcome of its board meeting held on 25th August 2025, correcting only the effective date of the statutory auditor's appointment (which remains 25th August 2025). The board approved the appointment of M/s Sarang Shivajirao Chavan & Associates (FRN 159649W) as the new Statutory Auditor for FY 2025-2026. The board also appointed Mr. Vivek Mukesh Yadav (DIN: 11033957) as an Independent Director of the company, effective the same date. The disclosure confirms Mr. Yadav is not debarred from holding director office by SEBI or any other authority. The letter is signed by Ms. Chaitali Kalpataru Shah, Director & CFO, indicating no change in that key position.
For shareholders, this is largely an administrative correction with no material change – the company has brought in a new statutory auditor and added an independent director to its board, which is routine governance housekeeping. Investors should note the change in audit firm as it may coincide with the start of a new financial year, but nothing in the filing signals distress or controversy.